BOLT (STOCKS)
Bolt Biotherapeutics, Inc. Common Stock
$4.660000
-0.250000 (-5.09%)
Prev close: $4.910000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- William P. Quinn
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $8.95M
- Employees
- 52
- P/E (TTM)
- -0.28
- P/B (TTM)
- 0.36
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-3.84 | $-6.23 | +2.3888 | +38.35% |
|
Sep 2025 (Q3)
|
$-3.72 | $-5.90 | +2.1838 | +36.99% |
|
Jun 2025 (Q2)
|
$-4.46 | $-6.58 | +2.1190 | +32.21% |
|
Mar 2025 (Q1)
|
$-5.80 | $-7.40 | +1.5950 | +21.57% |
Financial Statements
| Revenues | $55.89M |
| Benefits Costs and Expenses | $51.64M |
| Cost Of Revenue | $31.30M |
| Cost Of Revenue, Goods | $31.30M |
| Costs And Expenses | $51.64M |
| Gross Profit | $29.74M |
| Operating Expenses | $23.03M |
| Selling, General, and Administrative Expenses | $14.94M |
| Research and Development | $4.03M |
| Operating Income/Loss | $4.24M |
| Income/Loss From Continuing Operations After Tax | $3.90M |
| Income/Loss From Continuing Operations Before Tax | $9.03M |
| Income Tax Expense/Benefit | $4.53M |
| Income Tax Expense/Benefit, Deferred | -$123.00K |
| Net Income/Loss | $6.83M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $5.22M |
| Net Income/Loss Available To Common Stockholders, Basic | $5.22M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.45 |
| Diluted Earnings Per Share | $0.45 |
| Basic Average Shares | 26,037,831 |
| Diluted Average Shares | 26,067,862 |
| Assets | $82.59M |
| Current Assets | $53.49M |
| Inventory | $21.84M |
| Other Current Assets | $31.65M |
| Noncurrent Assets | $29.10M |
| Fixed Assets | $5.67M |
| Intangible Assets | $5.97M |
| Other Non-current Assets | $17.47M |
| Liabilities | $11.34M |
| Current Liabilities | $9.12M |
| Accounts Payable | $2.24M |
| Other Current Liabilities | $6.88M |
| Noncurrent Liabilities | $2.22M |
| Equity | $71.25M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $71.25M |
| Liabilities And Equity | $82.59M |
| Net Cash Flow From Operating Activities | $4.80M |
| Net Cash Flow From Operating Activities, Continuing | $4.80M |
| Net Cash Flow From Investing Activities | -$953.00K |
| Net Cash Flow From Investing Activities, Continuing | -$953.00K |
| Net Cash Flow From Financing Activities | -$7.19M |
| Net Cash Flow From Financing Activities, Continuing | -$7.19M |
| Net Cash Flow | -$3.34M |
| Net Cash Flow, Continuing | -$3.34M |
| Comprehensive Income/Loss | $3.90M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $3.90M |
| Other Comprehensive Income/Loss | $0.00 |